Pharmaron Beijing

300759.SZPre-clinical

Pharmaron Beijing is one of China's premier contract research organizations, serving both domestic and international pharmaceutical companies with end-to-end drug development services. The company has built significant capabilities across chemistry, biology, DMPK, toxicology, clinical research, and manufacturing. Listed on the Shenzhen Stock Exchange, Pharmaron has established itself as a key player in the global CRO market with operations primarily based in China and expanding international presence.

Market Cap

$5.6B

Employees

5,000-10,000

Focus

Biotech

300759.SZ · Stock Price

USD 26.2626.29 (-50.03%)

Historical price data

AI Company Overview

Technology Platform

Integrated contract research and development platform providing end-to-end pharmaceutical services from drug discovery through commercial manufacturing.

Funding History

Total raised: $200M

IPO$200MCICCNov 8, 2019

Opportunities

Pharmaron is positioned to capitalize on the growing trend of pharmaceutical R&D outsourcing, particularly in Asia-Pacific markets.

The company's integrated service platform and competitive cost structure provide significant opportunities for market share expansion as drug development costs continue to rise globally.

Risk Factors

Key risks include increased competition from global CROs, regulatory changes in China's clinical trial environment, and potential client concentration issues.

The company also faces challenges in maintaining quality standards while scaling operations rapidly.

Competitive Landscape

Pharmaron competes primarily with WuXi AppTec in China and global players like Charles River Laboratories and Covance internationally. The company differentiates through its integrated service offering, competitive pricing structure, and specialized expertise in Chinese regulatory requirements.

Publications